Open Science Policies and Practices Among Medical Journals - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Policies and Practices of Open Science in Medical Journals

  • By

  • Constant Vinatier

  • Ayu Putu Madri Dewi

  • Guillaume Freyermuth

  • Margaux Millour

  • Maud Scheidecker

  • François-Joseph Arnault

  • Mathieu Acher

  • Vladislav Nachev

  • Tracey L. Weissgerber

  • Nicholas J. DeVito

  • Gwénaël Dumont

  • Gowri Gopalakrishna

  • Gauthier Le Bartz Lyan

  • Inge Stegeman

  • Mariska M. G. Leeflang

  • Florian Naudet

  • September 4, 2026

Share

  • 1

    Biomedical journals play a crucial role in disseminating research essential for healthcare advancement and clinical decision-making.

  • 2

    Open science practices, such as study registration and data sharing, are increasingly viewed as key components of high-quality research.

  • 3

    The ICMJE mandated clinical-trial registration in 2005 and introduced data-sharing statements in 2018, but adherence remains limited.

  • 4

    A systematic evaluation of journals' open science practices is necessary to assess their transparency commitments and address predatory journals.

  • 5

    This study evaluated open science policies and practices in 10 leading medical journals using the TOP2025 guidelines and automated tools.

Original Source(s)

Open Science Policies and Practices Among Medical Journals

  • by Constant Vinatier, Ayu Putu Madri Dewi, Guillaume Freyermuth, Margaux Millour, Maud Scheidecker, François-Joseph Arnault, Mathieu Acher, Vladislav Nachev, Tracey L. Weissgerber, Nicholas J. DeVito, Gwénaël Dumont, Gowri Gopalakrishna, Gauthier Le Bartz Lyan, Inge Stegeman, Mariska M. G. Leeflang, Florian Naudet

  • September 4, 2026

Related Content

Biomarker may flag early pregnancy risk

A protein was linked experimentally to trophoblast invasion.

FDA approves first therapy for Alexander disease

The antisense oligonucleotide reduces production of the abnormal protein that accumulates in supportive cells in the brain.

Musings from The Power List: Peng Lu

Peng Lu argues that small molecules remain indispensable as AI transforms drug development

  • September 4, 2026

  • 4 min